MarketCapExport financials
Myomo (MYO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Myomo Income Statement 2025-2011 | MYO
Brief overview of financial results at Myomo
The figures are compared over a five-year interval. Myomo reported revenue of 7.6 million dollars in 2020 and 40.9 million dollars by 2025. Overall revenue changed by +439.7%, equal to an annualized rate of about 40.1%. The annual growth rate indicates an exceptionally strong top-line trend.
Gross profit changed from 5 million dollars to 26.9 million dollars (+439.6%). Revenue and direct costs changed at similar rates. Comparing the endpoints gives gross margins of 65.7% and 65.7%. The economics of the core business remained steady.
EBITDA was −$10.4 million at the beginning and −$13.5 million at the end of the period (−30.3%). Operating performance weakened relative to revenue. Comparing the endpoints gives EBITDA margins of −137.1% and −33.1%. A wider margin confirms stronger operating efficiency.
The final result was −11.6 million dollars initially and −15.6 million dollars in the final year. The period ended with a larger loss than it began with.
The five-year change in capitalization reached −18.8%: from $41.8 million to $33.9 million. The market became more cautious about the prospects of the business.
Financial takeaway
The figures do not all move in the same direction. Key strengths include steady gross profitability, revenue expansion and an improving EBITDA margin. Caution is warranted because of a weaker final result and a narrow EBITDA buffer. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Myomo
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
33.9 M | 30.6 M | 16.2 M | 5.64 M | 43.3 M | 41.8 M | 4.82 M | 20.9 M | 19.1 M | - | 65.3 K | - | - | - | - |
Shares |
41.9 M | 37.8 M | 29.5 M | 7.05 M | 5.83 M | 3.94 M | 554 K | 410 K | 144 K | - | 33.3 K | - | - | - | - |
Historical Prices |
0.81 | 0.81 | 0.55 | 0.8 | 7.43 | 11.1 | 4.64 | 36.3 | 138 | - | - | - | - | - | - |
Net Income |
-15.6 M | -6.2 M | -8.1 M | -10.7 M | -10.4 M | -11.6 M | -10.7 M | -10.3 M | -12.1 M | -3.62 M | - | - | - | - | - |
Revenue |
40.9 M | 32.6 M | 19.2 M | 1 B | 13.9 M | 7.58 M | 3.84 M | 2.44 M | 1.56 M | 1.1 M | - | - | - | - | - |
Cost of Revenue |
14 M | 9.37 M | 6.06 M | 5.3 M | 3.54 M | 2.6 M | 1.42 M | 728 K | 505 K | 282 K | - | - | - | - | - |
Gross Profit |
26.9 M | 23.2 M | 13.2 M | 10.3 M | 10.3 M | 4.98 M | 2.92 M | 1.72 M | 1.05 M | 821 K | - | - | - | - | - |
Operating Income |
-14.4 M | -6.21 M | -8.23 M | -10.7 M | -10.3 M | -10.5 M | -10.8 M | -10.5 M | -6.55 M | -3.28 M | - | - | - | - | - |
Interest Expense |
-668 K | 389 K | 240 K | 21.1 K | -15.3 K | -1.06 M | 82 K | 212 K | -5.55 M | -342 K | - | - | - | - | - |
EBITDA |
-13.5 M | -6 M | -8.07 M | -10.5 M | -10.1 M | -10.4 M | -10.7 M | -10.5 M | -6.54 M | -3.27 M | - | - | - | - | - |
Operating Expenses |
41.3 M | 29.4 M | 21.4 M | 20.9 M | 20.6 M | 15.5 M | 13.7 M | 12.2 M | 7.6 M | 4.1 M | - | - | - | - | - |
General and Administrative Expenses |
14 M | 12.4 M | 9.73 M | 18.4 M | 18 M | 13.8 M | 11.6 M | 10.4 M | 5.85 M | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Myomo
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
43.6 M | 42.7 M | 42.3 M | 118 K | 42.2 M | 41.6 M | 41.5 M | 399 K | 38 M | 37.4 M | 36.8 M | 1.96 M | 35.3 M | 28 M | 24.2 M | 171 K | 7.06 M | 6.92 M | 6.89 M | 300 K | 5.68 M | 5.64 M | 5.19 M | 428 K | 3.94 M | 2.93 M | 1.78 M | 574 K | 572 K | 570 K | 498 K | 415 K | 12.4 M | 12.4 M | 11.9 M | 11.1 M | 6.08 M | 2.31 M | 1.13 M | 1.12 M | 1.11 M | 1.02 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
-4.23 M | -4.02 M | -3.01 M | -3.81 M | -3.66 M | -4.63 M | -3.47 M | -260 K | -966 K | -1.12 M | -3.84 M | -2.46 M | -2.03 M | -1.01 M | -2.64 M | -2.17 M | -2.83 M | -2.91 M | -2.81 M | -3.37 M | -2.06 M | -2.62 M | -2.96 M | -1.7 M | -2.78 M | -3.29 M | -3.8 M | - | -2.79 M | -2.57 M | -3.4 M | - | -2.65 M | -2.63 M | -2.35 M | - | -1.26 M | -7.38 M | -12.1 M | - | -1.02 M | -760 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
12.3 M | 11.7 M | 10.1 M | 11.4 M | 10.1 M | 9.65 M | 9.83 M | 12.1 M | 9.21 M | 7.52 M | 3.75 M | 4.76 M | 5.08 M | 5.96 M | 3.45 M | 4.04 M | 3.97 M | 3.68 M | 25.9 K | - | 4.38 M | 3.1 M | 25.9 K | -300 | 109 K | 40.9 K | 1.01 M | - | 607 K | 880 K | 26 K | - | 609 K | 632 K | 75 K | - | 489 K | 307 K | 216 K | - | 184 K | 254 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
27 K | 72.9 K | 59.6 K | -23.6 K | 97.5 K | 60.2 K | 32.4 K | -11.7 K | 133 K | 122 K | 112 K | -11.7 K | 32.8 K | 266 K | 1.14 M | 1.41 M | 1.33 M | 1.28 M | 1.29 M | - | 1.11 M | 902 K | 113 K | 102 K | 83.6 K | 84.6 K | 319 K | - | 329 K | 125 K | 110 K | - | 194 K | 200 K | 127 K | - | 124 K | 98.6 K | 78.6 K | - | 77.1 K | 50.2 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
8.79 M | 8.44 M | 6.9 M | 7.78 M | 6.44 M | 6.05 M | 6.61 M | 8.62 M | 6.95 M | 5.33 M | 2.3 M | 3.1 M | 3.49 M | 4.28 M | 2.31 M | 2.63 M | 2.64 M | 2.4 M | 2.58 M | 3.12 M | 3.27 M | 2.2 M | 1.71 M | 2.78 M | 1.07 M | 440 K | 689 K | - | 277 K | 500 K | 543 K | - | 415 K | 432 K | 205 K | - | 364 K | 208 K | 138 K | - | 107 K | 204 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-1.72 M | -2.25 M | -3.16 M | -2.77 M | -3.52 M | -4.59 M | -3.52 M | -245 K | -958 K | -1.12 M | -3.89 M | -2.43 M | -2.02 M | -1.1 M | -2.67 M | -2.23 M | -2.82 M | -2.9 M | -2.74 M | -2.71 M | -2.03 M | -2.6 M | -2.93 M | -1.69 M | -2.55 M | -2.85 M | -3.42 M | - | -2.83 M | -2.71 M | -2.68 M | - | -2.71 M | -2.68 M | -2.4 M | - | -1.43 M | -1.93 M | -1.36 M | - | -934 K | -689 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
-2.41 M | -1.74 M | 334 K | -956 K | -9.74 K | 107 K | 192 K | 70 K | 76 K | 107 K | 135 K | 43.9 K | 41.7 K | 85.3 K | 69.1 K | 38.6 K | 12.3 K | -19.5 K | 52 | -5.14 K | -4.06 K | -6.02 K | -119 | -14.7 K | -230 K | -437 K | -379 K | - | 36.9 K | 141 K | 84.7 K | - | 58.6 K | 52.5 K | 57.5 K | - | 176 K | -5.45 M | -193 K | - | 84.4 K | 71.3 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
-1.72 M | -1.87 M | -2.87 M | -2.51 M | -3.27 M | -4.4 M | -3.36 M | -154 K | -909 K | -1.08 M | -3.86 M | -2.41 M | -1.99 M | -1.05 M | -2.62 M | -2.18 M | -2.77 M | -2.85 M | -2.69 M | -2.65 M | -1.99 M | -2.56 M | -2.91 M | -1.66 M | -2.52 M | -2.8 M | -3.4 M | - | -2.75 M | -2.68 M | -2.66 M | - | -2.66 M | -2.67 M | -2.39 M | - | -1.43 M | -1.93 M | -1.36 M | - | -928 K | -685 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
10.5 M | 10.7 M | 10.1 M | 10.6 M | 9.96 M | 10.6 M | 10.1 M | 8.86 M | 7.9 M | 6.44 M | 6.19 M | 5.54 M | 5.51 M | 5.38 M | 4.98 M | 4.86 M | 5.46 M | 5.3 M | 5.32 M | 5.83 M | 5.3 M | 4.8 M | 4.65 M | 4.47 M | 3.62 M | 3.29 M | 4.11 M | - | 3.1 M | 3.21 M | 3.23 M | - | 3.12 M | 3.11 M | 2.61 M | - | 1.8 M | 2.14 M | 1.5 M | - | 1.04 M | 892 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
3.58 M | 3.71 M | 3.62 M | 3.43 M | 3.18 M | 3.41 M | 3.94 M | 3.6 M | 3.25 M | 2.66 M | 2.87 M | 4.66 M | 4.8 M | 4.82 M | 4.5 M | 4.36 M | 4.77 M | 4.66 M | 4.66 M | 5.04 M | 4.66 M | 4.2 M | 4.12 M | 4.05 M | 3.27 M | 2.89 M | 3.6 M | - | 2.67 M | 2.78 M | 2.78 M | - | 2.67 M | 2.63 M | 2.24 M | - | 1.47 M | 1.43 M | 1.14 M | - | 803 K | 634 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Myomo (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Abbott Laboratories
ABT
|
$ 110.59 | 0.07 % | $ 193 B |  USA |
 |
EDAP TMS S.A.
EDAP
|
- | - | $ 162 M |  France |
 |
Align Technology
ALGN
|
$ 174.54 | 0.16 % | $ 12.7 B | USA |
 |
TELA Bio
TELA
|
$ 0.83 | -4.37 % | $ 39 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
$ 104.0 | -0.68 % | $ 60.8 B | USA |
 |
Avinger
AVGR
|
- | -20.74 % | $ 369 K | USA |
 |
CONMED Corporation
CNMD
|
$ 51.21 | -1.42 % | $ 1.59 B | USA |
 |
Medtronic PLC
MDT
|
$ 101.59 | -1.17 % | $ 130 B | USA |
 |
MiMedx Group
MDXG
|
$ 3.37 | 1.36 % | $ 498 M | USA |
 |
ThermoGenesis Holdings
THMO
|
- | -25.84 % | $ 171 K | USA |
 |
Talis Biomedical Corporation
TLIS
|
- | 3.55 % | $ 7.96 M | USA |
 |
Insulet Corporation
PODD
|
$ 148.03 | -1.19 % | $ 10.4 B | USA |
 |
Profound Medical Corp.
PROF
|
$ 7.66 | 4.36 % | $ 232 M |  Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.3 | -2.51 % | $ 141 M | USA |
 |
Viveve Medical
VIVE
|
- | -15.35 % | $ 1.71 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 30.96 | -0.29 % | $ 26.8 B |  Britain |
 |
Sensus Healthcare
SRTS
|
$ 3.42 | 7.39 % | $ 55.8 M | USA |
 |
Stryker Corporation
SYK
|
$ 324.18 | -0.48 % | $ 124 B | USA |
 |
Tactile Systems Technology
TCMD
|
$ 26.61 | 0.08 % | $ 609 M | USA |
 |
TransMedics Group
TMDX
|
$ 91.02 | -2.95 % | $ 3.09 B | USA |
 |
SmileDirectClub
SDC
|
- | -53.45 % | $ 9.71 M | USA |
 |
Viemed Healthcare
VMD
|
$ 9.04 | 1.01 % | $ 352 M | USA |
 |
Varex Imaging Corporation
VREX
|
$ 18.45 | 0.03 % | $ 764 M | USA |
 |
Acutus Medical
AFIB
|
- | -26.83 % | $ 2.62 M | USA |
 |
Vivos Therapeutics
VVOS
|
$ 0.09 | -8.14 % | $ 925 K | USA |
 |
BIOLASE
BIOL
|
- | -13.19 % | $ 166 K | USA |
 |
SeaSpine Holdings Corporation
SPNE
|
- | 0.28 % | $ 270 M | USA |
 |
Xtant Medical Holdings
XTNT
|
$ 0.28 | -0.68 % | $ 39.1 M | USA |
 |
Zimmer Biomet Holdings
ZBH
|
$ 107.39 | -0.87 % | $ 21.3 B | USA |
 |
Apollo Endosurgery
APEN
|
- | - | $ 475 M | USA |
 |
NuVasive
NUVA
|
- | - | $ 2.07 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.37 | 59.63 % | $ 24 M |  Israel |
 |
Penumbra
PEN
|
$ 321.48 | -0.11 % | $ 12.5 B | USA |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
ViewRay
VRAY
|
- | 1.54 % | $ 468 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | Israel |
 |
Boston Scientific Corporation
BSX
|
$ 44.68 | 1.49 % | $ 66.1 B | USA |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Neovasc
NVCN
|
- | - | $ 111 M | Canada |
 |
Vapotherm
VAPO
|
- | 6.72 % | $ 34 M | USA |
 |
Nevro Corp.
NVRO
|
- | - | $ 217 M | USA |
 |
Venus Concept
VERO
|
- | - | $ 726 K | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
Sientra
SIEN
|
- | -16.59 % | $ 10.3 M | USA |
 |
Silk Road Medical, Inc
SILK
|
- | - | $ 1.07 B | USA |
 |
Surgalign Holdings
SRGA
|
- | -32.98 % | $ 1.68 M | USA |
 |
Cardiovascular Systems
CSII
|
- | 0.15 % | $ 844 M | USA |
 |
ShockWave Medical
SWAV
|
- | - | $ 12.3 B | USA |
 |
Inari Medical
NARI
|
- | - | $ 4.23 B | USA |